Related Experiment Video
Updated: Jul 12, 2025

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
Published on: June 18, 2020
Further decompensation in cirrhosis: Results of a large multicenter cohort study supporting Baveno VII statements
Gennaro D'Amico1,2, Alexander Zipprich3, Càndid Villanueva4
1Gastroenterology Unit, Department of Medicine, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy.
Insights
Further decompensation in cirrhosis significantly increases mortality risk. This advanced stage of decompensated cirrhosis requires careful prognostic consideration.
Area of Science:
- Hepatology
- Clinical Medicine
- Prognostic Research
Background:
- The prognostic significance of recurrent decompensation events in cirrhosis patients remains incompletely understood.
- Cirrhosis management often focuses on initial decompensation, with less clarity on the impact of subsequent events.
Purpose of the Study:
- To determine the incidence of further decompensation in patients with cirrhosis.
- To evaluate the effect of further decompensation on patient mortality.
Main Methods:
- A multicenter cohort study involving 2028 cirrhosis patients.
- Utilized competing risks analysis and a 4-state model (first decompensation, further decompensation, liver transplant, death).
- Employed a cause-specific Cox model for adjusted mortality analysis, with sensitivity analyses for pre/post-1999 cohorts.
Main Results:
- Over a mean follow-up of 43 months, 52% of patients experienced further decompensation, and 35% died.
- Further decompensation was associated with a 1.46-fold increased hazard of death (adjusted HR: 1.46; 95% CI: 1.23-1.71; p <0.001).
- Ascites and its complications were the most frequent causes of further decompensation.
Conclusions:
- Further decompensation affects approximately 60% of cirrhosis patients, substantially elevating mortality.
- This condition represents a more advanced stage of decompensated cirrhosis, necessitating its recognition in clinical prognostication.
Background And Aims:
The prognostic weight of further decompensation in cirrhosis is still unclear. We investigated the incidence of further decompensation and its effect on mortality in patients with cirrhosis.
Approach And Results:
Multicenter cohort study. The cumulative incidence of further decompensation (development of a second event or complication of a decompensating event) was assessed using competing risks analysis in 2028 patients. A 4-state model was built: first decompensation, further decompensation, liver transplant, and death. A cause-specific Cox model was used to assess the adjusted effect of further decompensation on mortality. Sensitivity analyses were performed for patients included before or after 1999. In a mean follow-up of 43 months, 1192 patients developed further decompensation and 649 died. Corresponding 5-year cumulative incidences were 52% and 35%, respectively. The cumulative incidences of death and liver transplant after further decompensation were 55% and 9.7%, respectively. The most common further decompensating event was ascites/complications of ascites. Five-year probabilities of state occupation were 24% alive with first decompensation, 21% alive with further decompensation, 7% alive with a liver transplant, 16% dead after first decompensation without further decompensation, 31% dead after further decompensation, and <1% dead after liver transplant. The HR for death after further decompensation, adjusted for known prognostic indicators, was 1.46 (95% CI: 1.23-1.71) ( p <0.001). The significant impact of further decompensation on survival was confirmed in patients included before or after 1999.
Conclusions:
In cirrhosis, further decompensation occurs in ~60% of patients, significantly increases mortality, and should be considered a more advanced stage of decompensated cirrhosis.
Related Concept Videos
Chronic Pancreatitis II: Collaborative Care
Assessment:
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Varicose Veins II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Chronic Kidney Disease II: Clinical Manifestations

